Taken together, rapamycin inhibits highly activated mTOR signaling in TTLshort/high-risk ALL resulting in blocked proliferation of leukemia cells upon ex vivo exposure and, most importantly, after in vivo treatment of mice with manifest leukemia. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.